ViroPharma, Inc. (NASDAQ:VPHM)
A biopharmaceutical company dedicated to the development and commercialization of products that address serious infectious diseases, with a focus on products used by physician specialists or in hospital settings.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
A-.4 Star.
Recs
Poor sales growth, high volatility.
Recs
Nothing much to see here except some correction green thumbing. ViroPharma is getting dragged down along with most other biopharma mid caps despite the impressive growth in Cinryze sales. Vancocin revenues are shrinking to nothing but that was expected once the generic serpent hatched. The share price bottomed at 20 after the bad news broke about generics and then rose over 30 at the height of September's biopharma fever. The stock may well be headed back to 20 if broad market weakness continues, but at some point the winds will shift again.
Recs
There are currently 200 VPHM shares in my fund with break-even of around -2.79 USD.
http://caps.fool.com/Blogs/fund-trades/725331.
http://twitter.com/portefeuillefun.
Recs
Good pharma in pipeline
Recs
This one is looking good 4/28/11 may consider this on a good pullback. Like chart, statements, etc...
Recs
Magic Formula
Recs
stockmillionare.
Recs
zz and ultra.
Recs
Brings their the product to the rest of the world
Recs
any companythat can get seniors to pay 5,000 for meds to clear up hospital infection that medicare
will not cover is already a moneymaker!
Recs
As per this article: http://seekingalpha.com/article/220613-viropharma-a-tale-of-two-drugs?source=TheMotleyFool
Recs
CAPS=5/88
Recs
Bravobevo
Recs
VPHM has a too high valuation compared to its sales potential. It is also loss making.
Recs
will be trading in 9to10 range in three weeks
Recs
Recs
Short term holding till $13
Recs
Making great profits and increasing them year to year, 5.55 P/E today, I like it
Recs
I've been watching this stock for quite awhile and it finally hit my entry point. With this type of PE, for a biopharma, I see GOOD things, LONG term for this company.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 167 : 1 2 3 4 5 6 7 8 9 Next »